A Prospective, Noninterventional Follow-Up Study of Children Aged 23 to 25 Months, Born to Mothers Who Received Hydroxyprogesterone Caproate Injection, 250 mg/mL, or Vehicle for Prevention of Preterm Birth
Conditions
- Children Whose Mothers Received 17P and Those Who Received Vehicle in the 17P Efficacy Trial
Interventions
- DRUG: ASQ-3, Bayley III, Neurologic exam
Sponsor
AMAG Pharmaceuticals, Inc.
Collaborators